人民网北京9月23日电 （记者乔业琼）据国家医保局官网消息，近日，国家医保局印发《消化系统 医疗服务价格项目立项指南（试行）》与《疝、甲乳类医疗服务价格项目立项指南（试行）》，旨在促 进医疗机构提高诊疗质量、提升计价收费规范性。 国家癌症中心数据显示，我国消化道疾病发病率逐年攀升，胃癌、结直肠癌等消化道肿瘤位列癌症 发病率前5位，相关疾病的规范治疗更加重要。淋巴结清扫是外科手术中常见的治疗手段，尤其在肿瘤 或感染性疾病治疗时，这一操作有助于降低肿瘤复发风险、明确病理分期或改善患者预后。但是淋巴结 清扫多与其他治疗同时进行，在以往收费中就出现一些争议。 此次立项指南将淋巴结清扫单独列出，并明确"恶性肿瘤扩大根治性切除"所指的联合多脏器切除， 不含淋巴结清扫。以治疗结肠癌的"结肠部分切除费"为例，对于结肠癌肝转移患者，可收取结肠部分切 除费+恶性肿瘤扩大根治性切除（加收）+腹部淋巴结清扫费，使得收费层次分明、权责清晰，为临床 执行提供了明确指引。 区分手术难度，充分体现临床价值 疝是人体内器官或组织通过先天或后天形成的薄弱点、缺损或孔隙，常见的有腹股沟疝、脐疝、切 口疝等。由于疝的位置、大小等因素，手术难度差异大 ...

Group 1: Policy Initiatives - The National Healthcare Security Administration (NHSA) is focusing on technological innovation in the medical field, introducing a series of forward-looking pricing projects to support high-level innovations [1][4] - NHSA has released 27 batches of project guidelines, adding over 100 pricing items related to new products and devices [1] - A dynamic response mechanism has accelerated the implementation of policies, allowing for rapid local execution of pricing adjustments [2] Group 2: Specific Innovations and Pricing - In the field of artificial hearts, NHSA has introduced pricing for implantation, extraction, and adjustment services, reducing the overall cost of artificial heart surgeries from over 1 million yuan to around 700,000 yuan [1] - For cochlear implants, the NHSA has standardized the implantation fee to 3,500 yuan, significantly lowering the cost from over 200,000 yuan to 50,000 yuan [2] - New pricing projects for proton therapy, heavy ion therapy, and boron neutron capture therapy have been established to support cancer treatment advancements [2][3] Group 3: Market Impact and Future Directions - The NHSA aims to create a virtuous cycle of high-quality innovation leading to reasonable returns and continuous innovation in the healthcare sector [2] - The introduction of differentiated pricing for invasive and non-invasive brain-machine interfaces encourages companies to focus on niche markets, avoiding redundant competition [3] - NHSA is committed to maintaining an open attitude towards high-level new technology pricing, facilitating the rapid entry of innovative results into clinical practice [4]